Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 1, 2007, Pages 124-130

  Golden, Wendy M ^a   Weber, Katie B ^a   Hernandez, Teri L ^a   Sherman, Steven I ^b   Woodmansee, Whitney W ^a   Haugen, Bryan R ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; PLACEBO; THYROTROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33846039969     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0696     Document Type: Article

References (24)

1. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK 2001 Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637
2. Rigas JR, Dragnev KH 2005 Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10:22-33
3. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD 2003 Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21:999-1006
4. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V 2004 Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272-280
5. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR 2004 Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 3:1011-1020
6. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS 2001 The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol Endocrinol 15:1360-1369
7. Shen Q, Cline GW, Shulman GI, Leibowitz MD, Davies PJ 2004 Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. J Biol Chem 279:19721-19731
8. Ogilvie KM, Saladin R, Nagy TR, Urcan MS, Heyman RA, Leibowitz MD 2004 Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology 145:565-573
9. Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD 2002 Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 143:2880-2885
10. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley KNP, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor selective ligands. New Engl J Med 340:1075-1079
11. Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR 2006 Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology 147:1438-1451
12. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC 1997 The thyrotrope-restricted isoform of the retinoid X receptor (γ 1) mediates 9-cis retinoic acid suppression of thyrotropin β promoter activity. Mol Endocrinol 11:481-489
13. Breen JJ, Matsuura T, Ross AC, Gurr JA 1995 Regulation of thyroid-stimulating hormone β-subunit and growth hormone messenger ribonucleic acid levels in the rat: effect of vitamin A status. Endocrinology 136:543-549
14. Breen JJ, Hickok NJ, Gurr JA 1997 The rat TSH β gene contains distinct response elements for regulation by retinoids and thyroid hormone. Mol Cell Endocrinol 131:137-146
15. Esfandiari A, Gagelin C, Gavaret JM, Pavelka S, Lennon AM, Pierre M, Courtin F 1994 Induction of type III-deiodinase activity in astroglial cells by retinoids. Glia 11:255-261
16. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC 2001 Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581-593
17. Andersen S, Pedersen KM, Bruun NH, Laurberg P 2002 Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87:1068-1072
18. Samuels MH, McDaniel PA 1997 Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study. J Clin Endocrinol Metab 82:3700-3704
19. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J 2001 Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol Pharmacol 59:170-176
20. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti Jr JR, Heyman RA 1997 Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410
21. Singh AH, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ 2001 Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 59:765-773
22. Morley JE, Melmed S, Reed A, Kasson BG, Levin SR, Pekary AE, Hershman JM 1980 Effect of vitamin A on the hypothalamo-pituitary-thyroid axis. Am J Physiol 238:E174-E179
23. Macchia PE, Jiang P, Yuan YD, Chandarardna RA, Weiss RE, Chassande O, Samarut J, Refetoff S, Burant CF 2002 RXR receptor agonist suppression of thyroid function: central effects in the absence of thyroid hormone receptor. Am J Physiol Endocrinol Metab 283:E326-E331
24. Howell SR, Shirley MA, Ulm EH 1998 Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid X receptor selectivity and effects on metabolic enzymes. Drug Metab Dispos 26:234-239